Rebuttal
During the last decade, the role of evoked potentials (EPs) in multiple sclerosis (MS) has been experiencing a very promising conceptual change. EPs have been traditionally used to diagnose MS, but they are now demonstrating their more powerful and useful role in establishing the prognosis of the disease.
Evoked potentials provide functional information on sensory (visual, acoustic, somatosensory) and motor central nervous system (CNS) pathways. MS is an inflammatory disease of the CNS characterized by demyelination and axonal loss that lead to EP abnormalities such as delayed latency, morphological abnormalities, and wave cancellation or diminished amplitude. EPs can therefore provide additional information on the underlying pathologic process. Although these abnormalities are not specific for MS, a well-preserved EP morphology together with relevant latency delay is suggestive of a demyelinating disorder. EPs have been widely used in the past for the diagnosis of MS, but their use for this purpose has lessened considerably with the advent of magnetic resonance imaging (MRI). The usefulness of EPs in the assessment of disease activity is limited by the fact that, although they can also reveal clinically silent lesions, EP abnormalities are present only if their corresponding pathway is involved. In fact, although EPs can detect subclinical CNS involvement, their sensitivity to brain lesions is much lower compared with that of MRI, except for the identification of optic nerve involvement. Their importance in the diagnostic process of MS is of most benefit for the confirmation of a dubious relapse in patients complaining of vague or transitory symptoms.
From soon after the onset of MS, an ongoing process of neurodegeneration and axonal loss can be detected. This axonal loss seems to be the origin of the irreversible neurological changes that are responsible for the disease progression in MS. Up to 80% of MS patients may develop progressive disease 10-15 years after symptom onset. Once a given level is reached on the Expanded Disability Status Scale (EDSS) of around 4, which means limitation in walking, progression of disability occurs more or less independently of the exacerbations, and the rate of progression seems to be similar in all patients. 1 Nevertheless, the natural course of the disease typically shows a high interindividual variability because each patient takes a different time to reach a certain degree of disability. At present, we just have clinical scales like EDSS for measuring progression. It is therefore of crucial importance to find quantitative and objective markers of progression. Conventional MRI techniques correlate poorly with disability development and are of limited value. The measurement of grey matter atrophy appears to be a better predictor of disability development. But MRI techniques required to measure grey matter atrophy are highly specialized and not widely available, so they may not be practical in a clinical setting as a technique for assessing prognosis in MS. Another tool used to detect and measure axonal loss in MS is optic coherence tomography (OCT), measuring for example the thickness of the retinal nerve fiber layer (RNFL), which has the advantage that the axons are unmyelinated, or the ganglion cell layer (GCL). These measures provide an estimation of retinal axonal integrity and correlate with EDSS, but the technique is confined to visual system analysis. In contrast, EPs are widely available and can provide information about several functional CNS pathways; indeed, attempts have been made to monitor disease progression over time using EPs.
Amplitude and latency measures of EPs within a single modality are insufficient to assess the global functional status in MS patients. Multimodal EPs and non-parametric conventional scores may be useful to consider the severity of the morphological abnormality and the number of absent EP components within the same modality. 2 Motor evoked potentials (MEPs) elicited by transcranial magnetic stimulation of the motor cortex are of special interest in MS. Motor system involvement, mainly lower limb disability, has a high weight in determining the EDSS score. MEPs correlate very well with clinical disability expressed by the EDSS. 3 As in the other EP modalities, the pathological substrates of MS account for all the abnormalities detected by MEPs; however, and more especially to detect axonal loss, which may result in loss of amplitude and other abnormalities, MEPs should be done in a well-standardized way in order to provide accurate results.
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Multimodal EPs have been tested in prospective and retrospective studies in MS, [3] [4] [5] showing a very good correlation between EP measures and scales with EDSS and evolution time. Multimodal EPs were used prospectively in a homogeneous population of relapsing-remitting MS patients with early disease and found to be a robust biomarker of disability development. Specifically, a multimodal EP scale robustly predicted disability development at 3 years. The prognostic potential of EPs did not appear to be influenced by immunomodulatory therapy. 6 Studies incorporating both multimodal EPs and other techniques that measure neurodegeneration, like quantitative MRI evaluations or OCT measures, are therefore warranted to clarify whether a multiparametric approach may improve our prognostic ability in MS. In a prospective study including 89 MS patients, a multivariate analysis including multimodal EP and OCT measures (RNFL and GCL), the MEP amplitude of the upper limbs was the strongest measure correlating with EDSS in the multivariate analysis, and receiver operating characteristics (ROC) curve analysis showed an accuracy and discriminating power of 0.8 for detecting progression to EDSS >4. 7 Given the good correlations of EPs in detecting disease progression, EPs may be used to monitor the effects of drugs acting on nerve conduction and on neural protection and regeneration. In fact, several recent clinical trials designed to find neuroprotective effects in MS used EPs as objective tools to measure the therapeutic effects. 8 In conclusion, good correlation has been demonstrated between clinical assessment and EPs, and strong evidence favors the routine clinical use of multimodal EPs in the prognosis of MS. The integration of MRI, OCT and EP data may provide new prospects for understanding the pathological processes underlying the evolution of multiple sclerosis and, if validated, they could prove useful in monitoring the effects of neuroprotective treatments.
